Research output per year
Research output per year
Robert Hawkins is Cancer Research UK Professor at the University of Manchester and Christie Hospital. His research interests are in gene and immunotherapy of cancer. In addition to clinical training at the Royal Marsden Hospital and Addenbrookes Hospital in Cambridge he was an MRC Research Fellow with Dr Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology in Cambridge. His PhD was in antibody engineering and as a Cancer Research UK Senior Clinical Fellow he developed translational research interests in antibody based gene therapy. He was first appointed as a consultant in Medical Oncology at Addenbrooke’s Hospital in Cambridge in 1995 and then became Professor of Oncology at the University of Bristol in 1996. In 1998 he moved to the Christie Hospital to become Professor and Director of Medical Oncology. Clinically, Professor Hawkins focuses on treating renal cancer and cancer of the oesophagus/stomach. He heads a clinical research group undertaking trials in these cancers and also a range of early phase clinical trials of biological agents including vaccines, antibodies and cellular therapy. He has co-ordinated major grants from the European Union including the ATTACK projects and was coordinator of the ATTRACT integrated training network. He has published widely in scientific and clinical journals and is an inventor/co-inventor on several antibody related patents.
Professor Hawkins also lead the development of a Cellular Therapeutics Unit based at the University of Manchester Incubator Building to faciitate translational research in cell therapy for cancer. This GMP unit has developedi nto a successful biotechnology company developing adoptive cell therapy for cancer. The company also provides expert manufacturing services in other areas of cell therapy
American Society for Gene Therapy (ASGT)
International Society for Biological Therapy of Cancer (ISBTC)
British Association for Cancer Research (BACR)
American Society for Clinical Oncology (ASCO)
European Society for Gene and Cell Therapy (ESGCT)
European Society for Medical Oncology (ESMO)
Lab staff
Dr Gray Kueberuwa
Dr Milena Kalaitsidou, BSc, MSc, PhD.
Aoife Kilgallon, BSc, MSc (co-supervised by Dr Eleanor Cheadle, Dr Robert Clarke and Dr Anne Armstrong with honorary supervision by Dr David Gilham.)
Weiming Zheng BSc - (co-supervised by Dr Anne Armstrong, Dr Eleanor Cheadle and Dr John Bridgeman)
Abdulrahman Bahashwan, MBBS, MSc - (co-supervised by Dr Anne Armstrong, Dr Robert Wynn, Dr John Bridgeman, Dr Guy Makin and Dr David Gilham)
Adam Milner, MPhys (Hons) - (co-supervised by Dr Anne Armstrong, Dr Dominic Rothwell, Dr John Morris and Dr David Gilham)
Vanessa Clay, MBChB (Hons) and MRCP -MCRC-funded Clinical Fellow and PhD student (co-supervised by Dr Robert Clarke)
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Director / CEO Cellular Therapeutics Ltd
1 Apr 2016 → …
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Meeting Abstract › peer-review
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Article › peer-review
Dive, C., Baena Chaparro, E., Blackhall, F., Bruce, I., Bundred, N., Carter, L., Clarke, R., Cook, N., Crosbie, P., Evans, D., Harris, J., Hawkins, R., Hussell, T., Illidge, T., Jayson, G., Jorgensen, C., Kirwan, C., Kostarelos, K., Krebs, M., Lorigan, P., Marais, R., Marshall, K., Metcalf, R., Payne, K., Radford, J., Somervaille, T., Springer, C., Taylor, S., Thistlethwaite, F., Viros Usandizaga, A. & Zelenay, S.
1/04/17 → 31/03/19
Project: Research
Fiona Thistlethwaite (Corresponding participant), Robert Hawkins (Participant), Peter Stern (Participant) & David Gilham (Participant)
Impact: Technological impacts, Health and wellbeing, Economic, Policy
Chow, S. (Contributor), Galvis, V. (Contributor), Pillai, M. (Contributor), Leach, R. (Contributor), Keene , E. (Contributor), Spencer-Shaw, A. (Contributor), Shablak, A. (Contributor), Shanks , J. (Contributor), Liptrot , T. (Contributor), Thistlethwaite , F. (Contributor) & Hawkins, R. (Contributor), figshare , 18 Oct 2016
DOI: 10.6084/m9.figshare.c.3611852.v1, https://figshare.com/collections/High-dose_interleukin2_a_10-year_single-site_experience_in_the_treatment_of_metastatic_renal_cell_carcinoma_careful_selection_of_patients_gives_an_excellent_outcome/3611852/1
Dataset